The rare, deadly blood clots triggered by an autoimmune response to the COVID-19 vaccines from Johnson & Johnson and ...

Erasca is spending a combined $22.5 million upfront to import fresh preclinical KRAS and molecular glue assets while ...

On the heels of a groundbreaking FDA approval for a major medtech, a Silicon Valley startup is shaping up to be a possible ...

Atai Life Sciences, one of the leading shareholders in psilocybin drug developer Compass Pathways, is swapping CEOs.

Novo Nordisk is coming for Roche’s Hemlibra. A phase 3 trial of the Danish drugmaker’s challenger to the blockbuster ...

After picking up $100 million in venture capital cash earlier this month, Karius is adding another feather to its cap with a ...

Cytokinetics has set out to prove that aficamten is a threat to Bristol Myers Squibb’s $13.1 billion heart disease drug ...

Results from the phase 3 SUPERNOVA study show that the company’s investigational long-acting antibody (LAA) sipavibart ...

AC Immune is currently evaluating ACI-24.06 in a phase 1b/2 trial in subjects with prodromal Alzheimer’s disease as well as ...

Thermo Fisher Scientific has put forward a DNA-based test it says can offer much more precise identification of blood and its ...

Health has gathered $25 million in funding to help continue clinical studies of its less invasive, outpatient procedure for ...

Johnson & Johnson is shelling out $850 million to buy Proteologix, getting hold of a young roster of bispecific immunology ...